Global Pediatric Clinical Trails Market - Trends, Sizes and Forecast 2017 - 2022

  • ID: 4388631
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 4
The Global pediatric clinical trials market valued US $ xx million and is estimated to scale up to US $ xx million by the end of 2016. Considering the historical trend and possible future developments, the market is further estimated to reach a market value of US $ xx million by 2021, growing with an expected CAGR of xx% during the forecast period of 2016-2021.

Clinical trials for pediatric population have always been overshadowed by the trials in adults. Although the pediatric population holds a huge share in the total population, the number of clinical trials performed in adults are almost ten times more than that in pediatric population. However, in past 10-15 years the importance of clinical trials in pediatric has risen because of increasing understanding of difference between needs of children medication and adult medication. This is one the major driving force in the market. Another factor directly influencing to the market is the increasing burden of pediatric diseases such as diabetes, cancer etc. The type 2 diabetes which previously would be seen mostly in adults is now expanding its reach to pediatric population too. Diseases burden has given rise to the need to effectively tackle diseases in children. This need is eventually increased the number of clinical trials in children. As a result, in past decade many big pharmaceutical companies have tried their hands in this particular business segment. However, executing children as well as adult clinical trials became a herculean task for the companies. Due to this, in past 10-15 years the pharmaceutical companies have been outsourcing clinical trials to the contract research organizations (CRO). Contract Research Organizations serving the pharmaceutical industry generated a revenue of about $22 billion in the year 2010 globally. Global revenues are expected to reach more than $32 billion by 2016 and to exceed $65 billion by 2021, with the top 10 CROs accounting for more than half of the worldwide market. The shift of in-house clinical trials to CRO’s happens to be a driving force at the market side of the industry.

However, factors such as Ethical issues in pediatric research, relative rarity of pediatric diseases, small number of study population and lack of infrastructure in developing countries are hindering the growth of the market. The study sample size is one of the major restraint in adoption of children medicine as less than 100 patients are studied which often does not give a definite solution to the problem of disease heterogeneity in case of large and diverse population.

Market Segmentation by study design

In the report, the overall global pediatric clinical trials market is studied by focusing on each market segment that contributes to the total market value. For instance, the market in segmented into various phases of clinical trials such as phase 0, phase 1, phase 2, phase 3. On the basis of study design the market is segmented into various designs of studies such as Treatment studies which is further segmented into Randomized control trail (Double blind randomized, single blind randomized and non-blind trail), Adaptive clinical Trail and non-randomized clinical trials; observational studies which is further divided into cohort study (prospective cohort, retrospective cohort and time-series cohort), case control study and cross control study. Lastly, it is segmented into ecological study deign.

Market segmentation by Therapy Area

The market segmentation by therapy area covers pediatric clinical trials trends, market sizes and forecast about ID/Vaccines, CNS/Anesthesia/pain, Gastrointestinal, Immunology, oncology and other newly added areas under pediatric clinical trials.

In 2015 the pediatric clinical trials market by therapy area valued to $ xx million and is estimated to reach a market value of $ xx million by 2016 and $ xx million by 2021, growing with CAGR of xx % during the forecast period (2017 - 2022). Currently, Infectious diseases are is the largest accounting for xx% of the total market. However, clinical trials in the field of pediatric oncology is gaining popularity across the world. In recent times, pediatric oncology trails have attributed considerably to the overall market. Its indications can be seen in the statistics such as increase in survival rate up to 80% from previous 10% in Europe (according to European society of pediatric oncology). By considering this trend and the number of on-going clinical trials, the pediatric oncology market is expected to grow with a CAGR of xx% during the forecast period.

Geographical segmentation:

The market has also been geographically segmented into Asia-Pacific, Europe, North America, Middle East and North Africa, Latin America and the Rest of the World. The report also covers market information, data and forecast of various countries in these major geographical regions. Below are the countries covered in each region

North America: USA, Mexico and Canada

Europe: Germany, UK, France, Italy, Spain, Scandinavia and Rest of Europe

Asia Pacific: China, India, Japan, Australia and others

Middle East and Africa: Egypt, GCC and Rest of MEA

Latin America: Brazil, Argentina, Colombia and others

The report consist of exhaustive market study considering the country level market driving and restraining factors which influence the current and future market scenario.

Lastly, the report consists comprehensive profile of the companies operating in clinical nutrition market. Company overview, Financials, products and services, business strategy and SWOT analysis Of Major companies such as Quintiles, Parexel, PPD, Covance, Charles Rivers, Pfizer, Centerwatch and others
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Study deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast period years
1.6 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Market Dynamics
4.1 Porter's Five Forces
4.1.1 Bargaining Power of Suppliers
4.1.2 Bargaining Power of Consumers
4.1.3 Threat to new entrants
4.1.4 Threat to substitute products and services
4.1.5 Competitive Rivalry within the industry
5. Drivers, Restraints, Opportunities, and challenges Analysis
5.1 Market Drivers
5.1.1 Rising importance of pediatric medicine
5.1.2 Need to effectively tackle diseases in children
5.1.3 Shift of in-house clinical trials to CRO's
5.1.4 Increasing burden of pediatric diseases such as diabetes
5.2 Market Restraint
5.2.1 Ethical Issues in pediatric research
5.2.2 Relative rarity of pediatric diseases
5.2.3 Small number of study population
5.2.4 Lack of infrastructure in developing countries
6. Global Pediatric clinical trials market segmentation
6.1 Segmentation by phase
6.1.1 Phase 0
6.1.2 phase 1
6.1.3 phase 2
6.1.4 phase 3
6.2 Segmentation by Design
6.2.1 Treatment studies Randomized Control Trail Double Blind Randomized Single Blind Randomized Non-Blind Trail Adaptive Clinical Trail Non Randomized Clinical Trail
6.2.2 Observational Studies Cohort Study Prospective Cohort Retrospective Cohort Time-Series Cohort Case Control Study Cross Control Study
6.2.3 Ecological Study
6.3 By Therapy Area
6.3.1 ID/vaccines
6.3.2 CNS/Anesthesia/pain
6.3.3 Gastrointenstinal
6.3.4 Immunology
6.3.5 Oncology
6.3.6 Others
7. Market segmentation by Geography
7.1 North America
7.1.1 United States
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 United Kingdom
7.2.3 France
7.2.4 Italy
7.2.5 Spain
7.2.6 Scandinavia
7.2.8 Rest of Europe
7.3 Asia-Pacific (APAC)
7.3.1 China
7.3.2 Japan
7.3.3 India
7.3.4 Australia and New Zealand
7.3.5 South Korea
7.3.6 Rest of Asia Pacific
7.4 Middle-East and Africa
7.4.1 GCC
7.4.2 Egypt
7.4.3 South Africa
7.4.4 Rest of Middle-east & Africa
7.5 South America
7.5.1 Brazil
7.5.2 Argentina
7.5.3 Rest of Latin America
8. Competitive Landscape
8.1 Merger and acquisition analysis
8.2 New Product Launches
8.3 Agreements, Collaborations and Parterships
9. Key Vendor Analysis
9.1 Quintiles
9.2 Parexel
9.3 PPD
9.4 Covance
9.5 Charles Rivers
9.6 Pfizer
9.7 Centerwatch
9.8 Others
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Note: Product cover images may vary from those shown